Strengthening the diagnosis and treatment of metabolic associated fatty liver disease in breast cancer patients
10.3760/cma.j.cn.115807-20200630-00201
- VernacularTitle:关注乳腺癌患者代谢相关脂肪性肝病的诊治
- Author:
Lingquan KONG
1
;
Shen TIAN
;
Zhou XU
;
Hao LI
;
Juan WU
;
Fan LI
;
Hongyuan LI
;
Kainan WU
Author Information
1. 重庆医科大学附属第一医院内分泌乳腺外科，重庆 400016
- Keywords:
Breast cancer;
Concomitant diseases of breast cancer (CDBC);
Metabolic-dysfunction associated fatty liver disease (MAFLD);
Nonalcoholic fatty liver disea
- From:
Chinese Journal of Endocrine Surgery
2022;16(5):520-524
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic-dysfunction associated fatty liver disease (MAFLD) is a common concomitant disease of breast cancer. It is one of the main causes of liver damage during chemotherapy and also an important cause of liver damage during endocrine therapy or follow-up, which seriously affects the quality of life and prognosis of breast cancer patients. Nonalcoholic fatty liver disease was renamed as MAFLD, which changed the original "exclusive diagnosis" to "inclusive diagnosis" and the non-negligible role of metabolic factors in the occurrence and development of fatty liver disease was recognized, but the clinical attention is not enough at present. More attention should be paid to the diagnosis and treatment of MAFLD in breast cancer patients because the proportion and risk of metabolic disorders are higher than that in general people. In this article, we will focus on the clinical significance, prevention and treatment of the new definition of MAFLD in the comprehensive management of concomitant diseases of breast cancer, so as to further improve the quality of life and prognosis of breast cancer patients.
